Seppälä Toni T, Ahadova Aysel, Dominguez-Valentin Mev, Macrae Finlay, Evans D Gareth, Therkildsen Christina, Sampson Julian, Scott Rodney, Burn John, Möslein Gabriela, Bernstein Inge, Holinski-Feder Elke, Pylvänäinen Kirsi, Renkonen-Sinisalo Laura, Lepistö Anna, Lautrup Charlotte Kvist, Lindblom Annika, Plazzer John-Paul, Winship Ingrid, Tjandra Douglas, Katz Lior H, Aretz Stefan, Hüneburg Robert, Holzapfel Stefanie, Heinimann Karl, Valle Adriana Della, Neffa Florencia, Gluck Nathan, de Vos Tot Nederveen Cappel Wouter H, Vasen Hans, Morak Monika, Steinke-Lange Verena, Engel Christoph, Rahner Nils, Schmiegel Wolff, Vangala Deepak, Thomas Huw, Green Kate, Lalloo Fiona, Crosbie Emma J, Hill James, Capella Gabriel, Pineda Marta, Navarro Matilde, Blanco Ignacio, Ten Broeke Sanne, Nielsen Maartje, Ljungmann Ken, Nakken Sigve, Lindor Noralane, Frayling Ian, Hovig Eivind, Sunde Lone, Kloor Matthias, Mecklin Jukka-Pekka, Kalager Mette, Møller Pål
1Department of Surgery, Helsinki University Central Hospital, P.O. Box 340, 00029 HUS Helsinki, Finland.
2University of Helsinki, Helsinki, Finland.
Hered Cancer Clin Pract. 2019 Feb 28;17:8. doi: 10.1186/s13053-019-0106-8. eCollection 2019.
Recent epidemiological evidence shows that colorectal cancer (CRC) continues to occur in carriers of pathogenic mismatch repair () variants despite frequent colonoscopy surveillance in expert centres. This observation conflicts with the paradigm that removal of all visible polyps should prevent the vast majority of CRC in carriers, provided the screening interval is sufficiently short and colonoscopic practice is optimal.
To inform the debate, we examined, in the Prospective Lynch Syndrome Database (PLSD), whether the time since last colonoscopy was associated with the pathological stage at which CRC was diagnosed during prospective surveillance. carriers were recruited for prospective surveillance by colonoscopy. Only variants scored by the InSiGHT Variant Interpretation Committee as class 4 and 5 (clinically actionable) were included. CRCs detected at the first planned colonoscopy, or within one year of this, were excluded as prevalent cancers.
Stage at diagnosis and interval between last prospective surveillance colonoscopy and diagnosis were available for 209 patients with 218 CRCs, including 162 , 45 _, 10 and 1 carriers. The numbers of cancers detected within < 1.5, 1.5-2.5, 2.5-3.5 and at > 3.5 years since last colonoscopy were 36, 93, 56 and 33, respectively. Among these, 16.7, 19.4, 9.9 and 15.1% were stage III-IV, respectively ( = 0.34). The cancers detected more than 2.5 years after the last colonoscopy were not more advanced than those diagnosed earlier ( = 0.14).
The CRC stage and interval since last colonoscopy were not correlated, which is in conflict with the accelerated adenoma-carcinoma paradigm. We have previously reported that more frequent colonoscopy is not associated with lower incidence of CRC in carriers as was expected. In contrast, point estimates showed a higher incidence with shorter intervals between examinations, a situation that may parallel to over-diagnosis in breast cancer screening. Our findings raise the possibility that some CRCs in carriers may spontaneously disappear: the host immune response may not only remove CRC precursor lesions in carriers, but may remove infiltrating cancers as well. If confirmed, our suggested interpretation will have a bearing on surveillance policy for carriers.
最近的流行病学证据表明,尽管在专家中心进行了频繁的结肠镜检查监测,但致病性错配修复()变异携带者仍会继续发生结直肠癌(CRC)。这一观察结果与以下范式相冲突:只要筛查间隔足够短且结肠镜检查操作最佳,切除所有可见息肉应能预防绝大多数携带者患CRC。
为了为这场辩论提供信息,我们在前瞻性林奇综合征数据库(PLSD)中研究了自上次结肠镜检查以来的时间是否与前瞻性监测期间诊断出CRC的病理分期相关。通过结肠镜检查招募携带者进行前瞻性监测。仅纳入被InSiGHT变异解读委员会评为4级和5级(临床可操作)的变异。在首次计划的结肠镜检查时或此后一年内检测到的CRC作为现患癌症被排除。
209例患者发生218例CRC,包括162例、45例、10例和1例携带者,可获得诊断时的分期以及上次前瞻性监测结肠镜检查与诊断之间的间隔。自上次结肠镜检查以来<1.5年、1.5 - 2.5年、2.5 - 3.5年以及>3.5年检测到的癌症数量分别为36例、93例、56例和33例。其中,分别有16.7%、19.4%、9.9%和15.1%为III - IV期(=0.34)。在最后一次结肠镜检查后超过2.5年检测到的癌症并不比早期诊断的癌症更晚期(=0.14)。
CRC分期与自上次结肠镜检查以来的间隔无关,这与腺瘤 - 癌加速发展范式相冲突。我们之前曾报道,更频繁的结肠镜检查与携带者中较低的CRC发病率无关,与预期情况相反。相反,点估计显示检查间隔较短时发病率较高,这种情况可能与乳腺癌筛查中的过度诊断类似。我们的研究结果提出了一种可能性,即携带者中的一些CRC可能会自发消失:宿主免疫反应不仅可能清除携带者中的CRC前体病变,还可能清除浸润性癌症。如果得到证实,我们提出的解释将对携带者的监测策略产生影响。